SNT Stock Overview
Operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Syntara Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.046 |
| 52 Week High | AU$0.058 |
| 52 Week Low | AU$0.014 |
| Beta | 0.61 |
| 11 Month Change | 2.22% |
| 3 Month Change | 43.75% |
| 1 Year Change | 43.75% |
| 33 Year Change | -54.00% |
| 5 Year Change | -80.83% |
| Change since IPO | -89.78% |
Recent News & Updates
Recent updates
Improved Revenues Required Before Syntara Limited (ASX:SNT) Stock's 36% Jump Looks Justified
Jul 05
Syntara Limited (ASX:SNT) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Apr 29Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement
Mar 14We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely
Feb 28Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why
Oct 27Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque
Mar 01We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth
Jan 04
Shareholder Returns
| SNT | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 9.5% | -16.3% | 0.9% |
| 1Y | 43.8% | 35.0% | 17.7% |
Return vs Industry: SNT exceeded the Australian Pharmaceuticals industry which returned 35% over the past year.
Return vs Market: SNT exceeded the Australian Market which returned 17.7% over the past year.
Price Volatility
| SNT volatility | |
|---|---|
| SNT Average Weekly Movement | 12.5% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: SNT's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: SNT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 21 | Gary Phillips | syntaratx.com.au |
Syntara Limited operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. The company’s lead product candidate is SNT-5505, which is in Phase 2 trial to treat myelofibrosis, myelodysplastic syndrome, hepatocellular carcinoma, and pancreatic cancer, as well as scar prevention. It also develops SNT-4728 in Phase 2 trial for the treatment of neurodegenerative diseases comprising isolated rapid eye movement sleep behavior disorder (IRBD) and Parkinson’s disease; SNT-5382, which is a selective lysyl oxidase-like 2 inhibitor in Phase 1 trial to treat chronic fibrosis; and SNT-8370 for the treatment of inflammation.
Syntara Limited Fundamentals Summary
| SNT fundamental statistics | |
|---|---|
| Market cap | AU$63.16m |
| Earnings (TTM) | -AU$13.67m |
| Revenue (TTM) | AU$5.76m |
11.0x
P/S Ratio-4.6x
P/E RatioIs SNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNT income statement (TTM) | |
|---|---|
| Revenue | AU$5.76m |
| Cost of Revenue | AU$8.30m |
| Gross Profit | -AU$2.53m |
| Other Expenses | AU$11.13m |
| Earnings | -AU$13.67m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.01 |
| Gross Margin | -43.98% |
| Net Profit Margin | -237.09% |
| Debt/Equity Ratio | 0.2% |
How did SNT perform over the long term?
See historical performance and comparison